Asthma Study
A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaled (5?g/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma
Protocol ID
08-02-188
Protocol Description
The purpose of this research study is to see if the study drug, tiotropium inhalation solution delivered by the Respimat® inhaler, along with patients' usual asthma medications, is effective in helping to control ashma symptoms when compared to placebo. Another purpose is to see how safe the study drug is for patients to use.
Eligibility Criteria
Patients with asthma
Primary Investigator(s)
- Jill P. Karpel, MD